The Priority Review

The stream · Daily digest

The stream: Wednesday, October 7, 2026

4 briefs from ClinicalTrials.gov and FDA, grouped by desk. Each is two sentences from one primary source, linked to it.

Machine-summarized from primary sources; not independently reported. How we use automation

Clinical trials · 3

  1. Sagimet registers Phase 3 trial of denifanstat in moderate to severe acne vulgaris

    The study, first posted on ClinicalTrials.gov on October 7, 2026, plans to enroll 800 participants and begin in October 2026. After a 12-week treatment phase, about 530 participants may consent to a 40-week open-label extension.

    Source: ClinicalTrials.gov registry record, October 7, 2026

  2. Sanofi posts results of Phase 3 MenACYW conjugate vaccine study in infants and toddlers

    Results for the Phase 3 study comparing MenACYW conjugate vaccine (MenQuadfi) with Nimenrix were first posted on ClinicalTrials.gov on October 7, 2026. The 840-participant, randomized, triple-masked trial, completed on November 14, 2025, evaluated non-inferiority of the immunological response after a 1+1 vaccination schedule in healthy infants and toddlers.

    Source: ClinicalTrials.gov results record, October 7, 2026

  3. Instituto Grifols posts results of Phase II/III trial of plasma-derived AT-III concentrate

    The study enrolled 3 participants with Antithrombin III Deficiency and began on April 15, 2008. It was terminated after primary completion in December 2011.

    Source: ClinicalTrials.gov results record, October 7, 2026

Approvals · 1

  1. FDA approves tucatinib with trastuzumab and pertuzumab for HER2-positive breast cancer maintenance

    On October 7, 2026, the FDA approved tucatinib (Tukysa, Seagen Inc., a subsidiary of Pfizer) in combination with trastuzumab and pertuzumab for adults with unresectable locally advanced or metastatic HER2-positive breast cancer following induction treatment. The approval follows a randomized, double-blind, placebo-controlled trial of 654 patients that showed a median progression-free survival of 24.9 months versus 16.3 months in the placebo arm.

    Source: FDA approval notification, October 7, 2026